Eli Lilly's Jaypirca Receives FDA Approval for First-Line Treatment of CLL·SLL… Now Usable in Previously Untreated Patients Without 17p Deletion
Eli Lilly's blood cancer treatment Jaypirca (ingredient name pirtobrutinib) has expanded its scope of use in the United States to include first-line (initial) treatment of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Eli Lilly announced on the 2nd that the U.S. Food and

Eli Lilly's blood cancer treatment Jaypirca (ingredient name pirtobrutinib) has expanded its scope of use in the United States to include first-line (initial) treatment of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
Eli Lilly announced on the 2nd that the U.S. Food and Drug Administration (FDA) has approved an additional indication for Jaypirca. With this approval, Jaypirca can now be used to treat previously untreated adult patients with CLL or SLL who do not have 17p deletion.
Jaypirca is a non-covalent Bruton's tyrosine kinase (BTK) inhibitor with a mechanism of action different from existing covalent inhibitors. According to Lilly, Jaypirca is the first and only non-covalent BTK inhibitor to receive FDA approval.
Approval Based on Phase 3 'BRUIN CLL-313'
The basis for this indication expansion is the results of the phase 3 clinical trial 'BRUIN CLL-313.' The study compared the efficacy of Jaypirca versus bendamustine and rituximab (BR) combination therapy in 282 CLL/SLL patients without 17p deletion and no prior treatment.
After a median follow-up of 28 months, the Jaypirca treatment group showed significant improvement in progression-free survival (PFS) as assessed by an independent review committee compared to the BR treatment group. The hazard ratio (HR) was calculated at 0.20 (95% confidence interval 0.11–0.37), which was statistically significant. The median PFS of the Jaypirca group was not reached at the time of analysis, while that of the BR group was 33.5 months.
Response Rate of 94% and Complete Remission of 13%
The overall response rate (ORR) was 94% in the Jaypirca group and 81% in the BR group. The complete remission rate in the Jaypirca group was 13%, and the partial remission rate was 81%.
In terms of safety, in the BRUIN CLL-313 trial, 3.6% of patients treated with Jaypirca required dose reductions due to adverse reactions, and 4.3% permanently discontinued treatment. Serious adverse reactions occurred in 28% of patients, and serious adverse reactions occurring in 3% or more of patients included pneumonia.
The product information for Jaypirca includes warnings and precautions for infections, hemorrhage, cytopenias, cardiac arrhythmias, second primary malignancies, hepatotoxicity including drug-induced liver injury, and embryo-fetal toxicity.
Four Phase 3 Clinical Programs Underway
Jaypirca has already been used to treat adults with relapsed or refractory CLL/SLL who have previously been treated with covalent BTK inhibitors. This FDA decision opens the way for Jaypirca to be considered an initial treatment option not only for patients whose treatment has progressed considerably, but also for certain previously untreated patients.
Lilly is currently conducting four phase 3 clinical programs—BRUIN CLL-313, CLL-314, CLL-321, and CLL-322—evaluating Jaypirca across multiple treatment stages of CLL/SLL.
However, whether to actually use the treatment and the method of administration should be determined by medical professionals after comprehensively considering the patient's genetic characteristics, comorbidities, prior treatment history, and safety.
※ This article is based on FDA approval and clinical trial data released by Eli Lilly and is not intended to promote the use of any specific medication. Indication and safety information for medications may vary depending on national approval terms and the patient's condition. AI assisted in the writing of this article.
CBC Globe publishes verified stories with editorial review, source checks, and tenant-specific publication standards.

![AMPERS&ONE Reveals 'THRONE' Concept for First Full-Length Album 'PATHFINDER'... 'King's Way' Comeback on November 17 [Official]](/_next/image?url=https%3A%2F%2Fmedia.cbcglobe.com%2Ftenants%2Fcbc00000-0000-4000-8000-000000000001%2Fmedia%2Fcbc%2F2026%2F11%2F625974%2F39c533a2746373e2%2Fvariants%2Fhero.webp&w=1920&q=75)

